Cibus is an agricultural biotechnology company developing precision gene-edited plant traits using non-GMO gene editing technology (RTDS including TALEN and GRON). The company licenses gene-edited crop traits to seed companies for royalties, focusing on weed management, herbicide tolerance, and disease resistance in crops including rice, canola, and soybean. Following the June 2023 merger with Calyxt, Cibus operates as a public company (NASDAQ: CBUS) with over 1,000 issued or pending patents in gene editing for agriculture.
Cibus is publicly traded
This company is no longer available on our private secondary market. Shares can be traded publicly under its listed ticker.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2001
Employees
51–200
Total Funding
$216M
3 rounds
Appointed Craig Wichner as CEO, succeeding interim CEO Peter Beetham, who returns to President/COO
Leadership transition may reset strategic direction; watch for guidance changes
Priced $15M underwritten public offering, 6,976,744 shares at $2.15/share, closing ~Mar 27, 2026
Repeated dilutive raises signal ongoing cash-burn/liquidity pressure
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Total raised $216M across 3 rounds
Last updated 09-26-2026
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| Mar 2024 | Public Offering | $27.5M | — | |
| Jun 1, 2023 | Series F (Private Units) Press release | $118.5M | — | |
| Jun 26, 2018 | Series C Press release | $70M | — | Fidelity Management and Research Company |
Craig Wichner
Chief Executive Officer
Peter Beetham
President & Chief Operating Officer
Cornelis (Carlo) Broos
Chief Financial Officer
Greg Gocal
Co-Founder, Chief Scientific Officer & Executive Vice President
Jason Stokes
Chief Administrative Officer, General Counsel & Corporate Secretary
Noel Sauer
Senior Vice President, Research
James Radtke
Senior Vice President, Product Development
Rosa Cheuk Kim
Senior Vice President, Legal
Mark Finn
Chairman of the Board of Directors
Cibus has traded on the Nasdaq Capital Market under the ticker CBUS since June 1, 2023, when Cibus Global merged into Calyxt. The company remains public and is funding operations with successive equity raises: its annual report for 2025, filed March 17, 2026, discloses substantial doubt about its ability to continue as a going concern, and it has completed four underwritten offerings since listing - $12.0 million in September 2024, $27.5 million in June 2025, $20.0 million in January 2026 and $15.0 million in March 2026 - alongside a new shelf registration statement filed May 15, 2026. Cash and cash equivalents stood at $20.4 million on June 30, 2026, which management expects to fund planned operating and capital spending into early in the first quarter of 2027.
Cibus shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker to place an order.
Cibus raised $216M across 3 disclosed funding rounds prior to its public listing.
Cibus was founded by Greg Gocal in 2001.
Cibus is headquartered in San Diego, California.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.